TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis

International Journal of Biological Markers

Volumn 19, Issue 2, 2004, Pages 115-119

  Slesak, Barbara ^a   Harlozinska Szmyrka, A ^a   Knast, W ^a   Sedlaczek, P ^a   Einarsson, R ^b   van Dalen, A ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Diasorin SpA   (Italy)

^c Institute of Tumor Marker Oncology   (Netherlands)

Author keywords

CA 19 9; Chronic pancreatitis; Follow up; Pancreatic cancer; TPS

Indexed keywords

CA 19-9 ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; PANCREAS CANCER; PANCREATICODUODENECTOMY; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE;

EID: 4243180461     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080401900205     Document Type: Article

References (16)

1. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998; 35: 364-70.
2. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-6
3. Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 90-7.
4. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000; 89: 83-8.
5. Sobin LH, Hermanek P, Hutter RVP. TNM classification of malignant tumours, 4th edition. Geneva: International Union Against Cancer, 1987.
6. Pedrazzoli S, Beger HG, Obertop H, et al. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg 1999; 16: 337-45.
7. European Group on Tumor Markers. Tumor markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 1999; 19: 2811-5.
8. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109: 247-51.
9. Fernandez E, La Vecchia C, Porta M. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995; 11: 185-9.
10. Malka D, Hammel P, Rufat P, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51: 849-52.
11. Tanaka N, Okada S, Ueno H, Okusaka T, Ikeda M. The usefulness of serial changes in serum CA 19-9 levels in the diagnosis of pancreatic cancer. Pancreas 2000; 20: 378-81.
12. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000; 47: 1750-2.
13. Stieber P. Sensible use of tumor markers. J Lab Med 2001; 25: 327-36.
14. Beretta E, Malesci A, Zerbi A, et al. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 2428-31.
15. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462-8.
16. Minghini A, Weireter LJ, Perry RR. Specificity of elevated CA 19-9 levels in chronic pancreatitis. Surgery 1998; 124: 103-5.